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Abstract: The acid-base dissociation constant (pKa) of a drug is a key physicochemical parameter inﬂ  uencing many bio-
pharmaceutical characteristics. While this has been well established, the overall proportion of non-ionizable and ionizable 
compounds for drug-like substances is not well known. Even less well known is the overall distribution of acid and base 
pKa values. The current study has reviewed the literature with regard to both the proportion of ionizable substances and pKa 
distributions. Further to this a set of 582 drugs with associated pKa data was thoroughly examined to provide a representa-
tive set of observations. This was further enhanced by delineating the compounds into CNS and non-CNS drugs to inves-
tigate where differences exist. Interestingly, the distribution of pKa values for single acids differed remarkably between CNS 
and non-CNS substances with only one CNS compound having an acid pKa below 6.1. The distribution of basic substances 
in the CNS set also showed a marked cut off with no compounds having a pKa above 10.5.
The pKa distributions of drugs are inﬂ  uenced by two main drivers. The ﬁ  rst is related to the nature and frequency of occur-
rence of the functional groups that are commonly observed in pharmaceuticals and the typical range of pKa values they span. 
The other factor concerns the biological targets these compounds are designed to hit. For example, many CNS targets are 
based on seven transmembrane G protein-coupled receptors (7TM GPCR) which have a key aspartic acid residue known 
to interact with most ligands. As a consequence, amines are mostly present in the ligands that target 7TM GPCR’s and this 
inﬂ  uences the pKa proﬁ  le of drugs containing basic groups. For larger screening collections of compounds, synthetic chem-
istry and the working practices of the chemists themselves can inﬂ  uence the proportion of ionizable compounds and con-
sequent pKa distributions. The ﬁ  ndings from this study expand on current wisdom in pKa research and have implications 
for discovery research with regard to the composition of corporate databases and collections of screening compounds. Rough 
guidelines have been suggested for the proﬁ  le of compound collections and will evolve as this research area is expanded.
Keywords: pKa, dissociation constant, distribution, drugs, absorption, ADME, bioavailability, drug discovery, pharmaco-
kinetics, acids, bases, ampholytes
Introduction
An awareness of the inﬂ  uence of the acid-base dissociation constant, pKa, on the biopharmaceutical 
properties of drugs and chemicals has long been established within the pharmaceutical and chemical 
industry. As the majority of drugs are weak acids and/or bases, knowledge of the dissociation constant 
in each case helps in understanding the ionic form a molecule will take across a range of pH values. 
This is particularly important in physiological systems where ionization state will affect the rate at 
which the compound is able to diffuse across membranes and obstacles such as the blood-brain barrier 
(BBB). The pKa of a drug inﬂ  uences lipophilicity, solubility, protein binding and permeability which 
in turn directly affects pharmacokinetic (PK) characteristics such as absorption, distribution, metabolism 
and excretion (ADME)
1–5. The well established association between pKa and PK has also resulted in 
the requirement for pKa values to be measured for regulatory compliance (e.g. FDA
6). Formulation 
procedures for optimizing drug delivery also beneﬁ  t from the determination of the pKa. Given the 
importance of this parameter to the drug industry
7, it follows that an ability to estimate or measure
8 the 
pKa, together with a knowledge of their distribution, will be of great beneﬁ  t. This is particularly impor-
tant when contemplating the large number of compounds that can be considered for screening purposes 
(e.g. combinatorial libraries, third party compound collections). Ideally, these sets of compounds should 
be representative of drug-like substances as a whole with regard to the proportion of ionizables and the 
distribution of the pKa values themselves.
An estimate of likely ADME characteristics can be obtained using pKa values and various other prop-
erties such as molecular weight (MW), partition coefﬁ  cient (logP), number of hydrogen bond donors 26
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(hdon) and acceptors (hacc), and polar surface area 
(PSA)
9. The pKa values themselves represent useful 
pieces of physicochemical information but in isola-
tion they have limited value. From the perspective 
of designing combinatorial libraries or buying sets 
of compounds from third party suppliers then it is 
important to know what the overall proﬁ  le of a 
collection should resemble with regard to a range 
of physicochemical properties. Therefore, in order 
to complement properties such as MW, logP, hdon, 
hacc and PSA, information regarding the propor-
tions of acids and bases, and the distribution of pKa 
values is required. In medicinal chemistry there are 
many instances where research is inﬂ  uenced by 
rules of thumb. This could be described as a col-
lective wisdom amongst the medicinal chemistry 
community where the ‘rules’ have not been fully 
researched or described. Such might have been the 
case with the Lipinski study
10 where some of the 
underlying principles were roughly known and 
applied prior to their publication. Certainly for pKa 
distributions, these have not been fully documented 
in the literature. It is on this basis that the current 
study has sought to explore the proportions of acids 
and bases and to detail the distribution of pKa val-
ues for a set of general drug-like molecules.
Drug-likeness
In recent years there have been numerous studies 
exploring methods to improve the efﬁ  ciency of the 
early stages of new medicines research. The aim of 
all these studies has been to reduce the development 
time from the initiation of a project through to the 
selection of a clinical candidate. Much of it has 
focused on the ‘drug-like’ or ‘lead-like’ nature of 
screening compounds or synthetic candidates
10–14. 
The argument raised was that if compounds were 
selected for optimization that required a consider-
able number of synthetic cycles to produce novel 
analogues that address ADMET (T = toxicity) 
deﬁ  ciencies then this lengthened the time needed 
to arrive at a clinical candidate. If, however, the 
compound was ‘drug-like’, or perhaps more prefer-
ably ‘lead-like’
15 from the outset, then it should be 
easier to arrive at the appropriate biopharmaceuti-
cal properties and in a shorter timeframe
16. Such 
aspirations are based on sound logic and have been 
implemented within the current practices of the 
pharmaceutical industry
10,17. One of the simplest 
of these procedures is a structure and functional 
group ﬁ  lter that removes compounds considered 
unsuitable as hits such as those containing toxic 
functional groups
18.
Research into drug-like and lead-like concepts 
has explored a range of ideas looking at structural 
characteristics and physicochemical properties. 
These studies have included examinations of 
molecular frameworks
19,20, molecular proper-
ties
12–14, 21, 22 and the prediction of ADME param-
eters
23 to name but a few. In addition, compounds 
that target the CNS have also been analyzed to 
proﬁ  le their physicochemical characteristics and 
to predict CNS activity
24–26. As such, it is becom-
ing entrenched within the medicinal chemistry 
community to look extremely closely at the char-
acteristics of the molecules they deal with and to 
work on those known to have suitable properties. 
Once again, it makes logical sense to operate most 
of your time in areas where there is a history of 
successful outcomes and where efﬁ  ciencies can be 
garnered.
Our knowledge of the overall proportion of acids, 
bases and pKa distributions is less understood than 
other aspects of drug and lead-likeness. For exam-
ple, statements often describe drugs as ‘typically 
weak acids and/or weak bases’. The proportion of 
drugs with an ionizable group has been estimated 
at 95%
27 while an analysis of the 1999 World Drug 
Index (WDI
28) showed that only 62.9% of that col-
lection were ionizable between a pH of 2 and 12
29, 30. 
Wells also estimated that 75% of drugs are weak 
bases, 20% weak acids and the remainder contained 
non-ionics, ampholytes and alcohols
27. A breakdown 
of the WDI set of ionizable compounds showed that 
two thirds of them had either a single basic group 
or two basic groups (Figure 1A). The next major 
group of compounds containing one or two acids 
made up 14.6% of this set while simple ampholytes 
with one acid and one base comprised 7.5%. To 
analyze the WDI database (51,596 compounds) the 
Chem-X software
31 was used to discriminate acids 
and bases. The details of which functional groups 
were used is not easily discernable, however the 
concept of exploring a pKa range of 2–12 is admi-
rable given that the term ionizable used by Wells 
may possibly have encompassed a greater propor-
tion of compounds. This may also suggest why only 
62.9% of compounds in the WDI were considered 
of interest compared to Wells ﬁ  gure of 95%
27. It 
should be noted (and presumed) that the two sets of 
drugs considered by the individual authors would 
have differed. On a smaller set of compounds (n = 53) 
with known capacity to cross or not cross the BBB 27
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it was
32 concluded that “compounds with minimally 
one charge with a pKa <4 for acids and 
correspondingly a pKa >10 for bases do not cross 
the BBB by passive diffusion.” The references cited 
above are among the few that touch on both pKa and 
the proportion of ionizable compounds within a set 
of drugs. It may be that dealing with pKa is 
occasionally troublesome for a number of reasons, 
e.g. access to measured data is not simple, 
calculation of large numbers of pKa values is 
cumbersome and compounds may contain variable 
numbers of ionizable groups. Consequently the pKa 
does not lend itself to simple calculation and 
comparison, such as molecular weight or polar 
surface area (PSA) might allow.
pKa data sources and analysis
In order to conduct an analysis of the proportion 
of acids and bases, and pKa distributions, suitable 
databases of pKa values are required. Several sets 
of pKa values are available such as PhysProp 
(Syracuse Research Corporation, North Syracuse, 
USA), Williams compilation in Foye’s textbook
33, 
the Merck Index
34, Avdeef 
35, IUPAC and related 
compilations
36–41, CRC Handbook
42, Lange’s 
Handbook of Chemistry
43, ACD/labs software and 
database
44 as well as the general literature. In some 
cases these data resources do not assign pKa values 
to particular functional groups. The Williams set 
(see Methods for details)
33 used in this current 
study simply speciﬁ  es whether the pKa value is 
derived from an acid or a base and this feature was 
an important factor in selecting this dataset for the 
analysis. Other issues to keep in mind are data 
quality as these compilations stem from many 
laboratories. In an ideal world it would be prudent 
to return to the original study to investigate how 
the measurements were undertaken and how 
problems (e.g. apparent pKa values, decomposition, 
precipitation, poor UV absorbance, use of co-
solvents, complex multi functional compounds) 
were handled. This perhaps is another reason why 
the pKa distribution of drugs has not been described 
in detail for the analysis of drug-like character.
The goal of these analyses is to provide an 
indication of the spectrum of pKa values and the 
proportion of acids and bases within a drug 
discovery environment. This is with particular 
regard to drugs that have made it to the marketplace 
so that this may inﬂ  uence drug discovery processes 
in general. It could be envisaged that analyses of 
Figure 1. Pie charts showing the distribution of acids and bases from the ﬁ  ndings of Comer and Tam
29 outlining the survey conducted by 
Tim Mitchell
30 on the acid base distribution using the 1999 WDI database, (A); the results from the 582 Williams compound dataset
33, 
(B); the 174 CNS compound subset, (C); and the 408 non-CNS compound subset, (D). The data associated with these diagrams is given 
in Tables 1 and 2.
1 base, no acid
2 bases, no acid
1 acid, 1 base
1 acid, 2 bases
1 base, 2 acids
others
1 acid, no base
2 acids, no base
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D C28
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corporate collections, third party suppliers and 
combinatorial libraries (real or virtual) are 
undertaken to determine whether their distributions 
match that of marketed drugs. Following this, 
decisions could be made to add to collections where 
certain classes of compounds or pKa ranges are 
underrepresented and to influence synthetic 
directions. In the simplest sense it may add 
information regarding the overall composition of 
compound collections which can be discussed 
accordingly. Computational tools oriented to 
looking at ionizable groups as well as tautomer 
states
45 have recently been established. One 
example is the ProtoPlex module within Sybyl
46 
which can populate a database with alternative 
tautomers and protomers for each compound. 
Other workers have also striven to represent 
compounds in the most appropriate way by 
considering ionizable groups and tautomers. Kenny 
and Sadowski
47 described their technique which is 
able to apply formal charges to selected functional 
groups. They also emphasized the importance of 
their work in procedures such as virtual screening. 
Pospisil and co-workers also showed that tautomer 
state affected docking scores in virtual screening
45 
thus emphasizing the importance of considering 
pKa on how we conduct drug discovery. Overall it 
is clear that the pKa value(s) of a substance is 
fundamental to many areas of early and late stage 
discovery and that knowledge of pKa distributions 
will be similarly important to improve how we 
discover and develop new medicines.
Methods
To explore the proportion of ionizable compounds 
to non-ionizable compounds the World Health 
Organization’s (WHO) essential medicines list was 
employed (March 2005
48). This represents a list of 
“minimum medicine needs for a basic health care 
system”, together with a set of complimentary 
medicines for priority diseases. It may be viewed 
as a mini-pharmacopoeia, however the makeup of 
the set will differ somewhat to more extensive lists 
of drugs. Nevertheless it serves to encompass a 
range of drug classes for a wide range of medical 
needs. Compounds were classified into three 
groups: those with an ionizable group within the 
pKa range of 2–12 (determined using the ACD/labs 
software
44), those without an ionizable group and 
a miscellaneous set containing proteins, salts and 
others (e.g. gases, mixtures, polymers, metal com-
plexes, etc). The proportion of ionizable compounds 
was determined for the entire set and a selected 
subset that excluded the miscellaneous set.
The list of pKa values compiled by Williams
33 
was used as the source of data for the present study. 
An examination of the list was undertaken and the 
original set of 599 compounds was reduced to a 
ﬁ  nal set of 582 for analysis. Within this list the 
source references are given and most of the values 
come from Hansch in Comprehensive Medicinal 
Chemistry Volume 6
49 which is itself a secondary 
literature compilation. The Williams list
33 was 
chosen for its assignment of acids and bases, acces-
sibility and representation of a range of compound 
classes. The initial curation step included removing 
duplicates (e.g. bupivacaine and levobupivacaine; 
where the pKa is equivalent) and those compounds 
without a pKa value. For inclusion the compound 
was required to have a clinical use (either past or 
current use) or was considered safe for human 
consumption or represented an interesting chemo-
type (e.g. saccharin). Data misplaced in columns 
was adjusted and where pKa values for acid and 
base groups had been swapped this was amended. 
In some cases incorrect values were revised 
(e.g. tiaprofenic acid) and compounds with 
non-standard names were excluded where this led 
to ambiguity of the correct substance.
In addition to this examination, an assessment 
was made regarding whether the compound was 
intended for CNS use. In some cases this was not 
easy to deﬁ  ne particularly when the drug has been 
targeted towards peripheral sites but has CNS side 
Table 1. A list of the number of acids and bases in the 
Williams dataset
33 and associated subsets.
  No acid  1 acid  2 acids  3 acids
Entire dataset      
No base  0  142  22  3
1 base  264  65  16  4
2 bases  61  1  0  0
3 bases  4  0  0  0
CNS subset       
No base  0  27  2  0
1 base  108  13  0  1
2 bases  23  0  0  0
3 bases  0  0  0  0
Non-CNS subset      
No base  0  115  20  3
1 base  156  52  16  3
2 bases  38  1  0  0
3 bases  4  0  0  029
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effects. A classic example is the ﬁ  rst generation of 
histamine H1 receptor antagonists that were devel-
oped for the treatment of hay fever but often caused 
drowsiness. Where sedative activity was listed as 
an indication for the drug then it was annotated as 
a CNS drug (e.g. trimeprazine). Cocaine, albeit used 
clinically as a local anaesthetic, has well known 
CNS effects and was also classiﬁ  ed as a CNS sub-
stance. In some cases the classiﬁ  cation was difﬁ  cult 
to assign and, for the most part, the decision was 
based on the intended uses of the drug.
Analysis of the distribution of pKa values was 
applied to three groups of compounds: those contain-
ing a single acid, a single base and ampholytes with 
1 acid and 1 base. Histograms for the distributions 
required binning the compounds into ranges (i.e. 
0.5   X   1.5, 1.5   X   2.5, etc). In each case 
column heights were expressed as a percentage. 
Ampholytes (1 acid, 1 base) were also further classi-
ﬁ  ed as either ordinary (base pKa < acid pKa) or zwit-
terionic (base pKa >acid pKa) compounds. In order to 
plot and compare the ampholytes the isoelectric point 
was determined ([acid pKa + base pKa)/2] and the 
values binned in a similar manner to the pKa values.
Results
(a)  Acid and base proportions
The proportion of acids and bases in the Williams
33 
dataset of 582 compounds was determined by 
reviewing the pKa data and summing the number 
of compounds containing a single base, single acid, 
and so forth. Table 1 (Entire dataset) shows that 
almost half the compounds had a single base 
(45.4%) while single acid compounds made up 
about a quarter of the total (24.4%). Ampholytes 
comprised 14.8% of the total of which 65 com-
pounds (11.2%) were considered to be simple 
ampholytes containing a single acid and base. The 
other major group was those compounds with two 
basic groups representing 10.5% of the total. 
Figure 1B clearly shows the distribution of the 582 
compounds demonstrating that over half the com-
pounds are basic in nature (56.5%) [i.e. containing 
1, 2 or 3 basic groups without an acidic group].
Splitting the entire list into CNS (n = 174) and 
non-CNS (n = 408) compounds allowed the con-
struction of pie charts for each of these individual 
groups. Figure 1C, together with Table 1 (CNS sub-
set) show that the CNS class of compounds is 
dominated by those containing a single basic group 
(62.1%). If these compounds are combined with 
those possessing 2 bases this represents 75.3% of the 
total. The proportion of compounds containing a 
single acid was 15.5% while ampholytes 
(13 compounds) only made up 7.5% of this subset.
The non-CNS group of compounds showed a 
distribution similar to the entire dataset of 582 
compounds and this no doubt was inﬂ  uenced by 
the large number of compounds that make up this 
set (n = 408). Figure 1D and Table 1 (Non-CNS) 
demonstrate that compounds with one or two basic 
groups now comprise less than half the total 
(47.5%). The single acids comprised 28.2% and if 
combined with compounds containing two and 
three acids these make up about one third of the 
total. Simple ampholytes on the other hand made 
up 12.7% of this subset consisting of 52 com-
pounds. Table 2 compares the percentage of com-
pounds containing acids and bases between the 
Williams lists
33 and the analysis conducted on the 
WDI
29,  30. In general the WDI has fewer compounds 
containing a single acid and a greater number of 
compounds with two basic groups. The number of 
compounds with a single basic group was similar 
between the entire Williams list and the WDI.
The Williams
33 compilation did not, of course, 
list non-ionizable compounds as its prime interest 
was in those substances with a pKa value. To esti-
mate the proportion of non-ionizable compounds 
in a similar manner to the analysis by Comer and 
Tam
29,30 the WHO essential medicines list was used 
as a minimum set of therapeutic substances and 
compounds. The WHO list was consolidated to 
Table 2. Percentage of acid and base containing compounds in the Williams
33 and WDI datasets
28.
List  1 acid  1 base  2 acids  2 bases  1acid + 1 base  Others
Entire dataset 24.4  45.4  3.8 10.5 11.2  4.8
CNS subset 15.5  62.1  1.1  13.2  7.5  0.6
Non-CNS subset 28.2  38.2  4.9  9.3  12.7  6.6
WDI* 11.6  42.9  3.0  24.6  7.5  10.4
* Data taken from Comer and Tam
29,3030
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301 compounds from their March 2005 edition. Of 
these, 196 (65.1%) contained an ionizable group 
with a pKa in the range 2–12. This result is very 
similar to that obtained by Mitchell of 62.9%
29,  30. 
If we remove the miscellaneous compounds 
(e.g. proteins, salts, mixtures, polymers, gases, etc) 
from the analysis then we obtain a ﬁ  gure of 77.5% 
of compounds that contain a relevant ionizable 
group. This is in contrast to the 95% estimate of 
Wells
27 and may be a consequence of the small size 
of the WHO dataset and the inherent limitations 
for compounds to be included in the list. Alterna-
tively, Wells
27 may have included compounds with 
ionizable groups outside the pKa range of 2–12.
(b) pKa Distribution of single acid containing 
compounds
From the Williams set
33 single acid containing 
compounds consisted of 142 substances and a 
representative sample of these is shown in Figure 2. 
The distribution of pKa values is shown in Figure 3 
and this also illustrates both the CNS and non-CNS 
classes. Each column is given as a percentage to 
allow for the differing sizes of each group. An 
examination of all 142 acids shows that there is a 
bimodal distribution with a dip in numbers at a pKa 
of around 7.0. Compounds at the lower end of the 
scale largely contain carboxylic acids while those 
peaking around a pKa value of 8.0 contained a large 
proportion of barbiturates.
Within the CNS class only 27 compounds had 
a single acid. While this is a low number, the dis-
tribution of pKa values was nonetheless very inter-
esting. Figure 3 shows that the majority of acids 
had a pKa above 7 and only one fell below 6.1 
(valproic acid = 4.8).
When the non-CNS class was inspected the 
bimodal distribution of pKa values was again por-
trayed showing the dip in frequency close to 7.0. 
Within this set of 115 compounds those with lower 
pKa values were predominantly carboxylic acids.
(c) pKa Distribution of single base containing 
compounds
In contrast to the distribution of acids and perhaps 
as expected, the base pKa values peaked at a value 
of 9.0. The majority of compounds had a pKa value 
above 6.5 and these compounds typically contained 
a basic amine group. At the lower end of the pKa 
scale various functional groups were represented 
(e.g. nitrogen containing heterocycles). Figure 4 
shows a set of representative bases containing 
various heterocycles and amines. In all, 264 
compounds contained a single base making up just 
under half of the total set analyzed. Figure 5 shows 
the distribution of base pKa values ranging in value 
from 0.1 to 12.3. Once again the CNS and non-
CNS classes have been included to allow a 
comparison of the three groups.
The CNS class (n = 108) showed a clear cut off 
at the high end of the pKa scale. Indeed, there were 
no bases with a value above 10.5. Once again the 
majority of compounds had a pKa above 7 and 
mostly consisted of amines. The distribution for the 
non-CNS class closely matched the overall pattern 
found for the entire dataset with a peak in pKa values 
at around 9.0. pKa values for the non-CNS com-
pound set (n = 156) ranged from 0.3 to 12.3.
(d) pKa Distribution of simple ampholytes
In order to analyze the distribution of simple 
ampholytes (i.e. single acid and base) they were 
ﬁ  rst classiﬁ  ed as either ordinary or zwitterionic 
ampholytes and the isoelectric points were calcu-
lated. Figure 6 illustrates the range of isoelectric 
points for both the ordinary and zwitterionic 
ampholytes. While no clear pattern emerges this 
may be a reﬂ  ection of the limited number of com-
pounds (65) available for this analysis. The larger 
number of ordinary ampholytes at the high end of 
the scale represent simple phenols with alkylamine 
side chains (e.g. phenylephrine). If these com-
pounds are left aside, those that remain tend to have 
isoelectric points between 3.5 and 7.5.
When the CNS and non-CNS drugs were com-
pared interesting differences were observed. For 
the CNS class there were 13 simple ampholytes 
which made up only 7.5% of the 174 CNS com-
pound subset. Of these 13 compounds there were 
six opioids and six benzodiazepines all of which 
were ordinary ampholytes. In contrast, the non-
CNS subset contained 52 ampholytes comprising 
20 zwitterions and 32 ordinary ampholytes. No 
doubt the predominance of ordinary ampholytes 
in the CNS class reﬂ  ects the neutral character of 
these compounds at their isoelectric point where 
neutrality would favour CNS penetration.
Discussion
Overview of ﬁ  ndings
One concern over the analyses conducted in this 
study may be the choice of datasets used. This is 
a problem that plagues any analysis of drug sets 31
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that aim to tease out trends in physicochemical 
characteristics. The set employed should of course 
be representative of drugs as a whole to enable 
reasonable conclusions to be drawn. To look at the 
proportion of ionizables the WHO essential medi-
cines list
48 was used which represents a small 
pharmacopoeia for priority health care needs. It is 
overrepresented in certain drug classes (e.g. anti-
biotics) and lacks a range of medicines which are 
costly or merely enhance the quality of life 
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Figure 2. Chart showing nine acids with a range of pKa values. In each case the acidic group has been highlighted with an arrow. Penicillin 
G (1, pKa = 2.8), Flufenamic acid (2, pKa = 3.9), Valproic acid (3, pKa = 4.8), Glipizide (4, pKa = 5.9), Nitrofurantoin (5, pKa = 7.1), Pentobar-
bital (6, pKa = 8.1), Indapamide (7, pKa = 8.8), Metolazone (8, pKa = 9.7), Estrone (9, pKa = 10.8).32
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(e.g. selective serotonin reuptake inhibitors, HMG-
CoA reductase inhibitors, PDE 5 inhibitors, etc.). 
Nevertheless it is a well thought-out list covering 
the majority of therapeutic classes. In contrast, the 
WDI dataset used by Comer and Tam
29, 30 consisted 
of 51,596 compounds and could be viewed perhaps 
as a master list of drugs. The WDI, however, 
includes pesticides, herbicides and compounds that 
did not reach the market place. Given our desire 
to be representative of drugs it is not an ideal set 
and may be considered too encompassing. Our 
analysis therefore of the proportion of compounds 
that are ionizable is very dependent on the dataset 
used and provides results specific to that set. 
Another option is to examine all the drugs used 
commercially around the world such as those listed 
in Martindale
50. This contains over 5000 drug 
monographs and an analysis based on this set 
would be an onerous task. The obvious alternative 
is to choose a smaller set that has undergone an 
evolutionary process to select useful therapeutic 
substances (e.g. through evidence-based therapy), 
such as the AHFS Drug Handbook
51 (a subject of 
future research in this laboratory). Until such time 
that an agreed set of compounds can be selected 
to determine how many are ionizable the numbers 
generated here using the WHO list (65.1%) is 
comparable to the WDI ﬁ  ndings of Comer and 
Tam
29,30 (62.9%) and is far less than the 95% esti-
mate described by Wells
27. It is not clear which 
compounds Wells considered or how an ‘ionizable 
compound’ was deﬁ  ned. A more interesting analy-
sis might be where strict criteria are used for com-
pounds to be included in a survey. For example, 
organic compounds of molecular weight <1000 
together with a use in mammalian therapy in an 
oral (or injected) form. For small organic sub-
stances this would give a better indication of the 
proportion of compounds possessing an ionizable 
group.
The Williams list of compounds
33 could also be 
scrutinized in the same manner as the WHO essen-
tial medicines list. It is however, an extensive set 
of substances and represents a wide range of 
therapeutic classes. Once again better and more 
recent sets could be devised for this study and the 
Williams set was selected as a useful representative 
set and for the large number of compounds it con-
tained. As mentioned above this aspect of the study 
is being addressed in future work in these labora-
tories using the compounds listed in the AHFS 
Drug Handbook
51.
Until such time that these larger and more recent 
data sets are analyzed this present study provides 
an interesting insight into both the proportion of 
ionizable substances and the distribution of pKa 
values. The catch all phrase describing drugs as 
mainly ‘typically weak acids and/or weak bases’ 
certainly holds true when the pKa distributions are 
viewed (Figures 3 and 5). The power of the present 
analysis is to ﬂ  esh out the bones to this simplistic 
description and provides a starting point for 
Figure 3. Histogram showing the pKa distribution of compounds containing a single acidic group. Each group of columns contains a com-
parison of the entire set of single acids and those from the CNS and non-CNS subsets. Compounds were binned into 1 log unit ranges. For 
example, the column listed above 2.5 represents compounds with a pKa greater than 1.5 and less than or equal to 2.5.
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discussing pKa distributions. In particular, the 
apparent biphasic distribution of acid pKa values 
needs to be investigated further. Another important 
aspect to this research has been the scrutiny applied 
to CNS compounds. While, there is a general 
understanding concerning the principles behind 
the distribution of acid and base pKa values for 
CNS drugs, this has not been well documented or 
presented in the literature. For example, it is known 
about the paucity of CNS compounds with acid 
pKa values below 4.0 and base pKa values above 
10.0
32. Also recognized is the sensibility of these 
values as charged substances do not easily cross 
the BBB. Acids with pKa values below 4 will be 
in a charged state over 99% of the time at physi-
ological pH as will bases with a pKa above 10. The 
cutoff values described by Fischer and co-
workers
32 concur with the observations presented 
here, although only one compound had an acid pKa 
below 6.1. The important aspect of this present 
study was to outline the distributions themselves 
to demonstrate the spectrum of pKa values. Indeed, 
Figure 4. Chart showing nine bases with a range of pKa values. In each case the basic group has been highlighted with an arrow. Benzocaine 
(1, pKa = 2.5), Diazepam (2, pKa = 3.4), Cytarabine (3, pKa = 4.3), Tropicamide (4, pKa = 5.3), Amiodarone (5, pKa = 6.6), Droperidol (6, pKa = 7.6), 
Loperamide (7, pKa = 8.6), Atenolol (8, pKa = 9.6), Naphazoline (9, pKa = 10.9).
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the overall implication is that this is valuable infor-
mation when contemplating the properties needed 
for a drug or sets of screening compounds.
Application of ﬁ  ndings
The utility of the distributions described here may 
be applied to third party supplier databases for 
purchasing decisions regarding screening com-
pounds. Either the ratio of ionizable to neutral 
compounds could be applied or the pKa distribu-
tions could be used in the selection process. One 
thing that needs to be borne in mind is that the work 
described in this study has emerged from an 
analysis of drugs. Given that current screening 
efforts are oriented to lead-like molecules
15 then 
the distributions need to be considered in this light. 
Certainly an analysis of an ideal screening set of 
lead-like compounds would yield the appropriate 
data. In the absence of this we need to look at the 
guidelines suggested for lead-like character. These 
Figure 5. Diagram showing the pKa distribution of compounds containing a single basic group. Each group of columns contains a com-
parison of the entire set of single bases and those from the CNS and non-CNS subsets. Compounds were binned into 1 log unit ranges as 
per Figure 3.
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follow the criteria outlined here: MW < 350, logP < 3 
and afﬁ  nity approximately 100 nM
16. In other 
words there is scope for chemists to take a small 
molecule with reasonable activity and enter this 
into rounds of optimization for activity, selectivity 
and biopharmaceutical properties. The physico-
chemical criteria listed above are very simple, 
however pKa and logD are not considered. Perhaps 
a simple ratio of ionizable to non-ionizable com-
pounds needs to be suggested (e.g. 3:1, respec-
tively). Furthermore the makeup of the ionizables 
also needs to be considered by selecting com-
pounds with single acids, single bases and ampho-
lytes, in approximately the ratios outlined in Table 
2. More complicated combinations of acids and 
bases or those with 2 or more acids and bases 
should be kept to a minimum. These suggestions 
are purely speculative and are open to debate; suf-
ﬁ  ce to say that the compounds should contain a 
mix of neutral and ionizables in roughly the ratios 
seen for drugs as well as allowing chemists the 
possibility of adding further ionizable groups to 
enhance activity and biopharmaceutical character-
istics as part of the optimization process.
Perspectives and future directions
Ionizable groups on drug molecules have two 
principal functions. The ﬁ  rst is to modify overall 
polarity, which in turn controls other physico-
chemical properties, such as aqueous solubility or 
hydrophilicity. The second is to provide functional 
groups that can interact with target macromolecules 
in speciﬁ  c ways. Organic chemists, on the other 
hand, do not necessarily consider ionizable groups 
as ﬁ  rst priority groups to include on a novel com-
pound. A chemist, for ease of synthesis may prefer 
to work with non-polar compounds that are soluble 
in organic solvents. Another human consideration 
is the simplicity of the chemistry. Straightforward 
synthetic schemes will no doubt predominate to 
reduce the number of steps required. Given that 
ionizable groups often require protection means 
that additional synthetic steps are needed and 
introduces a further level of difﬁ  culty. Taking all 
this together suggests that organic compounds 
made to date will largely be lacking in ionizable 
groups. Furthermore, many of the third party sup-
pliers need a large number of new substances for 
their catalogues which means that a high through-
put is required from their chemists. High through-
put will be a driver for simpler chemistry and, using 
the argument above, will result in compounds lack-
ing ionizable groups. Of course, this trend has been 
identiﬁ  ed and is being speciﬁ  cally addressed for 
compounds with utility in medicinal chemistry. 
This refers to Lipinski’s
10 observations but the 
historic collections available will certainly be 
inﬂ  uenced by the (Darwinian) principle of ‘simple 
chemistry wins’.
Medicinal chemists also follow the principles 
of organic chemistry and prefer to introduce polar 
(ionizable) groups in the latter stages of a synthe-
sis (e.g. protecting group removal). The last step 
of a synthesis can also be engineered to be one that 
can introduce diversity to generate a set of ana-
logues. Third party screening compound suppliers, 
however, obtain a proportion of their catalogue 
from organic chemists rather than medicinal chem-
ists. As such it may be that these offerings do not 
follow the same acid/base/pKa distributions as 
drugs. Consequently, an examination of acid/base/
pKa distributions will be beneﬁ  cial to ensure that 
a suitable mix of compounds is chosen for screen-
ing, irrespective of the source.
An overriding question fundamental to this 
study concerns the pKa distributions themselves. 
Two separate inﬂ  uences will ultimately shape these 
ﬁ  ndings. The ﬁ  rst is chemical in nature concerning 
the functional groups that comprise the acid and 
base moieties. If we took the universe of organic 
compounds (a good representative subset might be 
the organic compounds contained in the CAS col-
lection) and produced pKa distribution plots then 
it would be possible to see how drugs compare. It 
may be that single acid containing compounds 
don’t exhibit a bimodal distribution and that drugs 
speciﬁ  cally lack groups with pKa values around 
7.0. Similar arguments could be directed at basic 
compounds and that the distributions we observe 
for drugs are a function of the regularly seen groups 
used in these compounds. Certainly, toxic func-
tional groups will be very limited in the Williams 
set
33 and this may also affect the pKa distribution. 
The second driver for the pKa distributions is bio-
logical in nature and is affected by membrane 
properties and the drug targets themselves. It is 
known that 7-transmembrane G-protein coupled 
receptors (7TM GPCR’s) have a key aspartic acid 
residue to recognize the amine group on their 
endogenous ligands
52. The need for an amine in 
drugs that interact with 7TM GPCR’s is almost an 
absolute requirement. If we combine this with the 
fact that a high percentage of drug targets are 7TM 
GPCR’s
53 then it will follow that amines will be 36
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well represented (particularly for CNS compounds) 
in the Williams set
33. Our knowledge of pKa dis-
tributions for a number of functional groups is quite 
reasonable but not when these are considered col-
lectively. Presumably the pKa value is a quantity 
which does not have a smoothly distributed con-
tinuum of values, but is necessarily multimodal 
because of the types of functional groups that exist 
in organic chemistry. In that sense, it is unlike logP, 
which has a much more broadly distributed set of 
values. This is a research area that will no doubt 
develop as larger populations of compounds are 
studied.
The task of identifying acids and bases in a 
database is a readily achievable task. A more dif-
ﬁ  cult procedure is to estimate the pKa values for 
these compounds. With regard to accuracy we 
preferably seek to predict within one log unit of the 
measured value. A variety of computational 
approaches are available and this topic was 
reviewed recently by Wan and Ulander
7. A number 
of methods are used within the commercial pack-
ages (e.g. ACD/Labs
44) such as the use of QSAR 
models based on Hammett analyses. Typically, a 
molecule is fragmented and the pKa of the func-
tional group is estimated by referring to a database 
of values with associated QSAR equations. Artiﬁ  -
cial neural network methods have also been used 
to estimate pKa and the software available from 
Simulations Plus is one such example
54. The ADME 
Boxes package from Pharma Algorithms
55 also 
estimates the total number of ionizable groups and 
predicts the principle pKa values. The other primary 
method of estimating pKa values is through quan-
tum mechanical techniques. The advantage here is 
that they can adapt to new chemical classes and do 
not necessarily need prior examples within the 
algorithm. In each case, and to differing degrees, 
estimates can be complicated by conformational 
ﬂ  exibility, solvent handling, conjugated systems 
and a lack of relevant examples. The needs of the 
pharmaceutical industry are challenging as they 
regularly explore novel structural scaffolds to enter 
new patent territory. If the software requires prior 
examples of a functional group or scaffold then 
accuracy may be compromised. For the purposes 
of characterizing a database, speed of calculation 
is a priority and may take precedence over accuracy. 
There are many computational hurdles yet to be 
tackled to provide a chemist friendly, fast and accu-
rate system of estimating pKa values within large 
databases (100,000’s compounds). Among the 
considerations are problems such as conformational 
flexibility, internal hydrogen bonding, solvent 
effects and multiprotic inﬂ  uences
7. Fortunately, 
several groups are working on better prediction 
methods and this will ultimately inﬂ  uence how we 
undertake research for new medicines.
Conclusion
This study has begun to explore the overall com-
position of drugs with regard to the proportion of 
those compounds containing an ionizable group. 
Within the WHO essential medicines list 65.1% of 
compounds had an ionizable group with a pKa in 
the range 2–12 and this number rises to 77.5% when 
non drug-like compounds are removed. Other esti-
mates give this number as anywhere between 
62.9%
29,30 and 95%
27. It is certainly clear that this 
ﬁ  gure is inﬂ  uenced by the collection being studied 
and how ‘ionizable’ is deﬁ  ned, and will be the 
subject of future research from our laboratories.
Analysis of Williams collection of drugs
33 has led 
to a description of the relative proportions of com-
pounds containing acidic and basic functionality. 
More importantly, the distribution of pKa values has 
been outlined in detail for the ﬁ  rst time. Two clear 
ﬁ  ndings emerged upon examination of the distribu-
tions particularly when a distinction was made 
between CNS and non-CNS drugs. Firstly, acid pKa 
values for CNS drugs rarely fell below 6.0 and sec-
ondly, base pKa values for CNS drugs were not 
observed above a value of 10.5. From an ionization 
viewpoint these observations are entirely reasonable 
when considering the nature of the BBB and the 
passage of charged substances across membranes. 
As such, these observations consolidate current 
wisdom in the area and open the way for larger col-
lections to be compared to these distributions.
Without doubt pKa is of paramount importance 
to the overall characteristics of a drug and has con-
siderable inﬂ  uence on biopharmaceutical proper-
ties. Current trends indicate that future research is 
placing an increased focus on pKa with the advent 
of high throughput measurement techniques and 
improvements to computational prediction soft-
ware
7. By taking pKa into account allows the 
researcher to begin ADME proﬁ  ling early in the 
discovery process. Moreover, with large collections 
of compounds such as corporate databases, third 
party supplier offerings and virtual sets of compounds 
(e.g. virtual combinatorial libraries), the researcher 
can examine both the proportion of ionizable 37
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compounds and with prediction methods can start 
to look at pKa distributions. If these differ largely 
from the observations outlined in the current study 
then it allows the opportunity to amend synthetic 
directions or screening compound selections.
The drive to consider the physicochemical 
properties of drugs to understand biopharmaceuti-
cal characteristics began many years ago (e.g.
10). 
This has fundamentally changed how discovery 
work is undertaken and was oriented to improving 
the efﬁ  ciency and productivity of pharmaceutical 
companies. Likewise, the need to explore pKa will 
begin to inﬂ  uence how we work. The ﬁ  ndings 
presented here go some way to understanding the 
distribution of pKa values and further guidelines 
will evolve as larger datasets are analyzed.
Acknowledgements
The author thanks Drs Richard Prankerd and David 
Chalmers for their insightful discussions and valu-
able suggestions.
Note
Since this article was written Lee et al. (Lee P.H., 
Ayyampalayam S.N., Carreira L.A., Shalaeva M., 
Bhattachar S., Coselmon R., Poole S., Gifford E. 
and Lombardo F. 2007 In Silico Prediction of 
Ionization Constants of Drugs. Mol., Pharm. 
4:498–512.) have described their SPARC program 
which predicts pKa values for drug-like com-
pounds. Comparisons of predicted against mea-
sured pKa values for a set of 123 drugs gave a root 
mean square error of 0.78 log units. The program 
is also capable of running in batch mode and may 
be extremely useful for characterizing large data-
sets of compounds. Interested readers can also view 
the software at http://sparc.chem.uga.edu.
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The Williams
33 dataset has been provided as sup-
plementary material.